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a b s t r a c t
Since the discovery of the role of tumor necrosis factor in the physiopathological process 
of rheumatoid arthritis, fi ve drugs that block this cytokine have been used as therapeutic 
options. To evaluate the effi cacy and safety of adalimumab in the treatment of rheuma-
toid arthritis we performed a systematic review and meta-analysis of randomized con-
trolled trials. A search of relevant studies in Medline (through PubMed) and LILACS in June 
2011 was carried out. Study selection, data collection and analysis were performed in pairs 
and independently by two reviewers and by a third reviewer in cases of disagreement. The 
meta-analysis was performed using the software Review Manager® 5.1 using the random 
effects model. Eleven articles related to adalimumab were included and considered nine 
studies with 3461 patients. Ten studies showed low risk of bias regarding the blinding of 
participants and personnel and blinding of outcome assessment. Patients who received 
the combination treatment of adalimumab and methotrexate showed better effi cacy re-
sults and lower radiographic progression when compared to placebo + methotrexate in 
24-104 weeks. Patients who received adalimumab as monotherapy showed better effi cacy 
outcomes when compared to placebo in 24 and 26 weeks. The results of the meta-analyses 
of adverse events were not statistically signifi cant, except for reactions at the injection site, 
which favored the control group. Adalimumab effi cacy was demonstrated in monotherapy 
and when associated to a DMARD, but the evidence for combined use is more robust.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Adalimumabe no tratamento da artrite reumatoide: uma revisão 
sistemática e metanálise de ensaios clínicos randomizados
Palavras-chave:
Artrite reumatoide
Adalimumabe
Fator de necrose tumoral
Revisão sistemática
Metanálise
r e s u m o
Desde a descoberta do papel do fator de necrose tumoral no processo fi siopatológico da artri-
te reumatoide, cinco medicamentos bloqueadores dessa citocina têm sido empregados como 
opção terapêutica. Para avaliar a efi cácia e a segurança do adalimumabe no tratamento da ar-
trite reumatoide foi conduzida uma revisão sistemática com metanálise de ensaios clínicos 
controlados e randomizados. Foi realizada busca de estudos relevantes nas bases de dados 
Medline (via PubMed) e LILACS em junho de 2011. A seleção dos estudos, coleta e análise de 
dados foram realizadas de forma pareada e independente por dois revisores e por um ter-
ceiro revisor em casos de discordância. A metanálise foi conduzida no software Review Ma-
nager® 5.1 usando o modelo de efeitos aleatórios. Onze artigos referentes ao adalimumabe 
foram incluídos e contemplaram nove estudos com 3461 pacientes. Dez estudos mostraram 
baixo risco de viés quanto ao cegamento dos participantes e pessoal e cegamento de avalia-
ção de resultados. Os pacientes que receberam tratamento da associação de adalimumabe 
e metotrexato apresentam melhores resultados de efi cácia e menor progressão radiográfi ca 
quando comparados ao grupo placebo + metotrexato em 24 a 104 semanas. Os pacientes que 
utilizaram adalimumabe em monoterapia apresentaram melhores resultados de efi cácia em 
relação ao placebo em 24 e 26 semanas. Os resultados das metanálises de eventos adversos 
não foram estatisticamente signifi cantes, exceto para reações no local de aplicação, na qual 
favoreceu o grupo controle. A efi cácia do adalimumabe foi demonstrada em monoterapia e 
associado a algum MMCD, porém as evidências para o uso combinado são mais robustas.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Evidence-based Medicine is the conscientious, explicit and 
sensible use of best evidence for decision-making in patient 
care. The practice of evidence-based Medicine integrates the 
individual experience of the physician with the best evidence 
available through systematic research.1
Systematic reviews are considered Level I evidence and 
have stringent methods that decrease the occurrence of bi-
ases when compared to narrative reviews.2 The benefi ts of the 
monoclonal antibody adalimumab in the control of rheuma-
toid arthritis (RA) have been widely reported in the literature 
and, in Brazil, this is the second most used drug of this class of 
biological agents for the treatment of this disease.3-5 The an-
nual cost of this treatment is high, being estimated in Brazil 
at R$ 71,117.00 and with a ratio of incremental cost-effective-
ness per quality-adjusted life year (QALY), when compared to 
therapy with methotrexate (MTX), of R$ 628.124,00.6 This high 
cost emphasizes the importance of systematization of all the 
evidence available to aid decision-making in health care. 
RA is a systemic infl ammatory, chronic and progressive 
disease of unknown etiology that affects the synovial mem-
brane of joints, leading to cartilage and bone destruction. This 
autoimmune disorder affects the joints, often in the hands 
and feet, on both sides equally and symmetrically.3,7 The prev-
alence is estimated at 0.5-1.0% of the population and is more 
frequent in women, according to studies performed in the 
United States, Europe and Brazil.8,9  
The care of patients with RA includes the use of disease-
modifying antirheumatic drugs (DMARDs), nonsteroidal anti-
infl ammatory drugs (NSAIDs) and corticosteroids, in addi-
tion to non-pharmacological treatment such as occupational 
therapy and physical therapy.10 Biological DMARDs represent 
a breakthrough in therapy and RA and have been indicated in 
cases where patients do not respond to conventional treat-
ment. 
The tumor necrosis factor (TNF) blockers adalimumab, 
etanercept, infl iximab, certolizumab and golimumab are in-
cluded in this class.3,10,11
Aiming to contribute to the practice of evidence-based 
Medicine, we performed a systematic review and meta-anal-
ysis of randomized controlled trials to evaluate the effi cacy 
and safety of Adalimumab in the treatment of RA. 
Methods
This study is part of a systematic review of randomized con-
trolled trials on the effi cacy and safety of the drugs adalim-
umab, etanercept, infl iximab and rituximab in the treatment 
of rheumatoid arthritis. 
Eligibility criteria 
Randomized controlled trials written in Portuguese, English 
and Spanish were selected for the review. We considered 
comparisons of Adalimumab 40 mg once every 15 days as 
monotherapy or combined with DMARDs vs. control group in 
patients with rheumatoid arthritis diagnosis according to the 
revised criteria of the American College of Rheumatology and 
active disease.12
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Article search 
The search for studies was carried out in the Medline data-
base (through Pubmed) and LILACS in June 2011 and sup-
plemented by manual searching in references of systematic 
reviews and the studies that were found. The search strat-
egy consisted of the following words: rheumatoid arthritis, 
monoclonal antibodies, D2E7 antibody, Humira®. The search 
in Pubmed was structured from Mesh (Medical Subject 
Headings) terms and a sensitive search was performed for 
randomized controlled trials. 
Study selection and data collection
Study selection was carried out by analysis of the titles and 
abstracts of studies selected by the search. Data were collect-
ed using a standardized form.
Two reviewers independently assessed and extracted data 
from each study and disagreements were resolved by consen-
sus or by a third reviewer. Data on characteristics of the study 
design and the population, duration of disease, previous or 
concomitant use of DMARDs, intervention and outcomes 
were collected for each trial.
The primary outcome was the ACR20 response defi ned 
by the American College of Rheumatology (ACR). ACR20 re-
sponse occurs when there is a decreased of 20% in the count 
of joints with pain and edema and improvement in 3 of the 
5 variables: overall assessment by the patient and physician, 
pain, Health Assessment Questionnaire (HAQ) scale and acute 
phase infl ammatory markers (C-reactive protein or erythro-
cyte sedimentation rate - ESR).13 The secondary outcomes 
were ACR50 and ACR70 responses, in which there are 50% 
and 70% improvement in the same parameters, in addition to 
functionality, measured by the HAQ scale, radiographic out-
comes, loss to follow-up and safety. The authors, if necessary, 
were contacted to provide additional information. 
Methodological quality and risk of bias
The assessment of methodological quality and risk of bias 
was performed independently by two reviewers with access 
to the author’s name, institution and the journal that pub-
lished the study and disagreements were resolved by consen-
sus. Quality assessment by the modifi ed Jadad scale and risk 
of bias assessment proposed by the Cochrane Collaboration 
were employed. These tools assess methodological aspects, 
such as randomization, blinding and loss of participants. The 
modifi ed Jadad scale scores clinical trials from 0-6 and the 
higher the score, the better the methodological quality.14, 15
Meta-analysis
The meta-analysis was performed using the Review Manag-
er® 5.1 software. We used the weighted difference in means 
for continuous outcomes and relative risk for dichotomous 
data, both considering a confi dence interval of 95%. 
The presence of heterogeneity between studies was con-
sidered a premise and therefore the random effects model 
was applied. Statistical heterogeneity was considered if P < 
0.10 for the chi-square test and I2 > 40% and in those cases, 
the potential factors that infl uenced this phenomenon were 
investigated.16 
Results 
The search for studies of the four drugs (Adalimumab, Etan-
ercept, Infl iximab and Rituximab) resulted in 3620 articles in 
Pubmed and 84 in LILACS, as well as nine articles found by 
manual search. Eleven articles related to Adalimumab were 
included and considered nine studies with 3461 patients 
(Fig. 1).
Study characteristics 
Seven studies evaluated groups of patients treated with 
Adalimumab (ADA) 40 mg every 2 weeks combined with some 
DMARDs vs. DMARDs as monotherapy (plus placebo): in six 
studies patients used MTX and in the STAR study subjects 
received some DMARDs, among them MTX, chloroquine, 
hydroxychloroquine, lefl unomide, parenteral gold, oral gold 
Search result: 3704
PubMed: 3620
Lilacs: 84
Excluded by title: 1203
Excluded by type of study: 417
Excluded by type of participant: 115
Excluded by type of intervention: 71
Excluded by type of outcome: 600
Total number of articles excluded by
abstract: 1594
Excluded by type of study: 1186
Excluded by type of participant: 78
Excluded by type of intervention: 77
Excluded by type of outcome: 253
Total number of articles excluded
by the full text: 30
Excluded by type of study: 22
Excluded by type of outcome: 01 
Excluded by type of intervention: 07 
Total number of articles included
by the full text: 30
Adalimumab: 11
Infliximab: 10
Etanercept: 20
Rituximab: 14
Manual search: 9
Duplicates: 11Total number of articles included in the
searches: 3713
Total number of articles included after
removing the duplicates: 3702
Total number of articles included by title:
2499
Total of articles included by abstract: 905
Total of observational studies that will
be analyzed at the next phase: 820
Total number of controlled and randomized
clinical trials included by abstract: 85
Fig. 1 – Diagram of the selection process for the inclusion of 
randomized controlled trials in the systematic review.
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compounds, sulfasalazine, or any combination of these.17 
Most patients (82.1% group ADA + DMARDs and 84.9% group 
placebo + DMARDs) used one or more DMARDs during the 
study and MTX was the most common (56.0% group ADA 
+ DMARDs and 62.6% group placebo + DMARDs). Two trials 
were performed in groups using ADA 40 mg every 2 weeks as 
monotherapy compared to placebo. Only the PREMIER study 
included arms of comparison between ADA monotherapy vs. 
MTX monotherapy.18  
Patients had active RA in all studies. The study GUEPARD 
defi ned active disease by DAS28 (disease activity score) great-
er than or equal to 5.1.19 The other studies defi ned it by count-
ing the joints involved, ranging from 9 to 12 tender joints and 
6 and 10 swollen joints. Furthermore, the PREMIER and DE019 
studies included patients with positive rheumatoid factor or 
at least one joint with erosion.18,20-22 
The GUEPARD and PREMIER studies evaluated treatment-
naïve patients with MTX. 18,19,20 The STAR study included 
treatment-naïve patients or those who had failed MTX ther-
apy, whereas others showed data from individuals with pre-
vious use or treatment failure with DMARDs.17 The GUEPARD 
and PREMIER studies considered patients with short disease 
duration, with a mean ranging from 4-8 months in the ran-
domized groups, while the mean in the remainder ranged 
from 7-11 years.18,19,20 The number of swollen and tender 
joints at baseline was similar among trials, except in the 
GUEPARD study, which showed lower values  for these mea-
sures (Table 1).19 
No authors declared freedom from confl icts of interest. The 
GUEPARD study was funded by the French Society of Rheu-
matology and the treatment with Adalimumab was provided 
by the Abbott laboratory.19 Chen et al. reported no source of 
funding and all other studies declared Abbott pharmaceutical 
industry support.23 
Methodological quality and risk of bias 
The GUEPARD study showed a value in the modifi ed Jadad 
scale equal to three (low quality) by not being double-blind, 
two (11.1%) had a score equal to four (appropriate quality), 
while fi ve studies (55.6%) showed score of fi ve and one study, 
by van de Putte et al., had a score of six, indicating high qual-
ity.19.24 The mean score was 4.66 (Table 2).
Only in the study by van de Putte et al., methods of ran-
domization and allocation concealment for interventions 
after randomization were reported, even though all studies 
were described as randomized.24 Therefore, as these methods 
were considered appropriate, only that study showed low risk 
of bias in allocation concealment (selection bias) and in the 
generation of random allocation sequences (selection bias). 
The allocation concealment is an important aspect in the de-
sign of a study, because when this procedure is appropriately 
carried out, one can prevent selection bias in the allocation 
of intervention, by protecting the allocation sequence until 
interventions are allocated (Table 2).15
The study of van de Putte et al. showed a high risk of bias 
in relation to incomplete reporting of outcomes, as the loss 
to follow-up was signifi cantly different between the groups 
(56.4% in the placebo group and 28.3% in the ADA group).24 
The GUEPARD study, for not being double-blind, showed a 
high risk of bias in the criteria of blinding of participants and 
personnel (performance bias), and blinding of outcome as-
sessment (detection bias).19 The other studies showed low risk 
of bias in these two items (Table 2).
The inter-examiner agreement level showed an almost 
perfect agreement (kappa = 0.831, SD = 0.675) in the assess-
ment of the methodological quality by the modifi ed Jadad 
scale and substantial agreement (kappa = 0.654, SD = 0.571) in 
the analysis of risk of bias.25
Effi cacy
Adalimumab 40 mg + DMARDs vs. placebo + DMARDs
Patients who used ADA + DMARDs were more likely to achieve 
ACR20, ACR50 and ACR70 responses at 24 weeks when com-
pared to patients from the group placebo + DMARDs (Fig. 2). 
The relative risk (RR) with confi dence interval (CI) of 95% to 
achieve ACR20 response was 1.92 (1.50; 2.47) with high het-
erogeneity (I2 = 66%, P = 0.01). We excluded studies to assess 
which of them would be infl uencing heterogeneity and it was 
observed that after removing the ARMADA study 26 the RR 
(95%CI) was 1.73 (1.48; 2.02) with no statistically signifi cant 
heterogeneity (I2 = 24%, P = 0.26) (Fig. 2).17,19,21,23,27 
In up to 24 weeks, the ACR50 response showed RR (95% CI) 
of 2.91 (2.00; 4.24), with high heterogeneity (I2 = 59%, P = 0.03). 
The exclusion of the study by Chen et al.23 increased the RR 
(95% CI) to 3.23 (2.35; 4.44) and statistical heterogeneity may 
not be signifi cant (I2 = 41%, P = 0.15).17,19,21,26,27 In up to 24 weeks, 
the ACR70 response was 4.02 (2.77; 5.96), with no statistically 
signifi cant heterogeneity (I2 = 3%, P = 0.40) (Fig. 2).17,19,21,23,26,27
The sources of heterogeneity for the studies by Chen et al. 
and ARMADA are not clear.23,26 The exclusion of the GUEPARD 
study, the only non-double-blind trial, from the three meta-
analyses did not alter the level of heterogeneity and statisti-
cal signifi cance of the results.19 
In 52 weeks of treatment, the results of meta-analyses 
showed no statistical signifi cance and showed high hetero-
geneity (I2= 90-96% and P ≤ 0.001).18,21 The isolated studies 
indicated statistically signifi cant differences between the 
comparison groups, favoring ADA + MTX therapy. The mag-
nitude of the response was greater in the DE019 study, when 
compared to PREMIER. This difference, as well as the high het-
erogeneity found in the meta-analyses, can be explained by 
the fact that the PREMIER study included patients with early 
disease (up to one year of diagnosis) and treatment-naïve pa-
tients with MTX, while the DE019 study evaluated patients 
with a mean of 11 years of disease and treatment failure with 
DMARDs.18,21
Jamal et al., in a continuation of the DE019 study, found 
that patients with early disease (≤ 3 years) and with estab-
lished disease (> 3 years) showed the same response profi le, 
always in favor of the intervention group.22 
In the analysis of 104 weeks, only the PREMIER study was 
included.18 The RR (95% CI) for ACR20 was 1.23 (1.08; 1.41), for 
ACR50 was 1.36 (1.15; 1.62) and for ACR70 was 1.68 (1.33; 2.12), 
favoring the ADA + MTX group.
The comparison of ADA monotherapy vs. MTX was per-
formed only by the PREMIER study, which showed no statis-
tical difference favoring the MTX group, only for ACR20 re-
sponse at 52 weeks, although with a borderline confi dence 
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Table 1 – Basal characteristics of the studies included in the systematic review.
Study (time of 
follow-up)
Patients 
(n)
Age (years) 
mean (SD)
Time of disease 
duration (years) 
mean (SD)
Patients that 
used DMARDs 
previously n (%)
Edematous joints 
mean (SD)
Painful joints 
mean (SD)
Patients using 
steroids n (%)
Patients using 
NSAIDs n (%)
HAQ mean 
(SD)
STAR (Furst et al., 
2003) - 24 weeks17
636
ADA 40 mg every 2 
weeks + DMARDs
318 55.0(12.8) 9.3(8.8) 292(91.8) 20.9(11.0) 27.3(13.0) 162(50.9) 198(62.3) 1.37(0.62)
MMCD 318 55.8(12.4) 11.5(9.7) 295(92.8) 21.3(11.2) 27.6(13.8) 173(54.4) 203(63.8) 1.43(0.60)
ARMADA (Weinblatt 
et al., 2003) - 24 
weeks26
271
ADA 40 mg  every 2 
weeks + MTX
67 57.2(11.4) 12.2(11.1) NI 17.3(8.6) 28.0(12.7) NI NI 1.55(0.61)
MTX 62 569(10.8) 11.1(8.0) NI 16.9(9.5) 28.7(15.2) 36(58.1) NI 1.64(0.63)
DE019 (Keystone et al., 
2004)-52 weeks21
619
ADA 40 mg every 2 
weeks  + MTX
207 56.1(13.5) 11(9.2) NI 19.3(9.8) 27.3(12.7) SI NI 1.45(0.63)
MTX 200 56.1(12.0 10.9(8.8) NI 19.0(9.5) 28.1(13.8) 99(49.5) NI 1.48(0.59)
DE019 (Jamal  et al., 
2009) - 52 weeks22
407
ADA 40 mg every 2 
weeks + MTX≤3 
years
41 49.7 1.8 NI 22.1 29.5 23(56.1) NI 1.5
MTX ≤ 3 years 37 52.6 1.9 NI 19.2 30.1 13(35.1) NI 1.5
ADA 40 mg every 2 
weeks + MTX > 3 
years
166 57 13.3 NI 18.7 26.9 74(44.6) NI 1.4
MTX > 3 years 163 56.3 12.9 NI 19.1 28 58(35.6) NI 1.5
Kim et al. (2007) - 24 
weeks27
128
ADA 40 mg every 2 
weeks  + MTX
65 48.5(10.2) 6.8(4.2) 65(100) 12.2(5.6) 19.2(9.2) NI NI 1.4(0.6)
MTX 63 49.8(10.5) 6.9(4.5) 63(100) 12.8(5.8) 20.3(8.6) NI NI 1.3(0.6)
PREMIER (Breedveld 
et al., 2006) - 104 
weeks18
799
ADA 40 mg every 2 
weeks  + MTX
268 51.9(14.0) 0.7(0.8) 87(32.5) 21.1 (11.2) 30.7 (14.2) 96(35.8) NI 1.5(0.6)
ADA 40 mg every 2 
weeks
274 52.1(13.5) 0.7(0.8) 91(33.2) 21.8 (10.5) 31.8 (13.6) 100(36.5) NI 1.6(0.6)
MTX 257 52.0(13.1) 0.8(0.9) 81(31.5) 22.1 (11.7) 32.3 (14.3) 91(35.4) NI 1.5(0.6)
(continued on next page)
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Table 1 – Basal characteristics of the studies included in the systematic review (continued).
Estudo (tempo de 
acompanhamento)
Pacientes 
(n)
Idade (anos) 
média (DP)
Tempo de duração 
doença (anos) 
média (DP)
Pacientes que 
usaram MMCD 
prévio n (%)
Articulações 
edemaciadas 
média (DP)
Articulações 
dolorosas 
média (DP)
Pacientes em 
uso de esteroides 
n (%)
Pacientes em 
uso de AINES 
n (%)
HAQ média 
(DP)
PREMIER (Kimel et al., 
2008) - 104 weeks 20
ADA 40 mg every 2 
weeks + MTX
268 51.9(14.0) 0.7(0.8) 87(32.5) 21.1 (11.2) 30.7 (14.2) 96(35.8) NI 1.6(0.6)
MTX 257 52.0(13.1) 0.8(0.9) 81(31.5) 22.1 (11.7) 32.3 (14.3) 91(35.4) NI 1.5(0.6)
Chen et al. (2009) - 12 
weeks26
47
ADA 40 mg every 2 
weeks  + MTX
35 53.0(29.0-75.0)≠ 6.2(0.3-19.1)≠ 35(100) 21.9 32.5 NI NI 1.7(1.5-1.9)≠
MTX 12 53(35.0-73.0)≠ 8.3(1.3-15.6)≠ 12(100) 24.1 37.2 NI NI 1.8(1.5-2.1)≠
GUEPARD (Soubrier et 
al., 2009) - 52 weeks19
65
ADA 40 mg every 2 
weeks  + MTX
33 46.3(16.3) 0.4(0.2-0.5)± SI 9.5 13.8 NI 10(30.3) 1.69(0.59)
MTX 32 49.3(15.2) 0.4(0.3-0.4)± NI 10.8 14.1 NI 10(31.3) 1.41(0.74)
Van de Putte et al. 
(2004) - 26 weeks24
544
ADA 40 mg every 2 
weeks
113 52.7(13.3) 10.6(6.9) NI 20.5(10.6) 33.7(15.9) 77(68.1) 93(82.3) 1.83(0.59)
Placebo 110 53.5(13.2) 11.6(9.3) NI 19.8(9.3) 35.5(14.2) 74(67.3) 92(83.6) 1.88(0.64)
CHANGE (Miyasaka et 
al., 2008) - 24 weeks28
352
ADA 40 mg every 2 
weeks 
91 56.9(10.3) 9.9(7.9) 91(100) 19.1(7.3) 24.4(10.7) NI NI 1.64(0.70)
Placebo 87 53.4(12.8) 8.4(8.2) 87(100) 19.3(7.0) 23.7(8.8) NI NI 1.39(0.75)
ADA, adalimumab; NSAIDs, nonsteroidal anti-infl ammatory drugs; SD, standard deviation; HAQ, Health Assessment Questionnaire; DMARDs, disease-modifying antirheumatic drugs; MTX, 
methotrexate; NI, no information.
± median (interquartile interval). 
≠ median (amplitude).
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Table 2 – Risk of bias proposed by the Cochrane Collaboration11 and modifi ed Jadad scale score10 of the methodological 
quality of the studies included in the systematic review.
Study Random 
generation 
of allocation 
sequence 
(selection bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection bias)
Incomplete 
outcome data
Selective 
reporting of 
outcomes
Modifi ed 
Jadad scale
Van de Putte et al., 
200424
Low risk Low risk Low risk Low risk High risk Uncertain 6
PREMIER 
(Breedveld 2006; 
Kimel 2008)18,20
Uncertain Uncertain Low risk Low risk Low risk Low risk 5
DE019 (Keystone  
et al., 2004; Jamal 
et al.,2009)21,22
Uncertain Uncertain Low risk Low risk Low risk Low risk 5
Kim et al., 200727 Uncertain Uncertain Low risk Low risk Low risk Low risk 5
ARMADA 
(Weinblatt et al., 
2003)16
Uncertain Uncertain Low risk Low risk Low risk Low risk 5
CHANGE 
(Miyasaka et al., 
2008)28
Uncertain Uncertain Low risk Low risk Low risk Low risk 5
Chen et al., 200923 Uncertain Uncertain Low risk Low risk Low risk Low risk 4
STAR (Furst et al., 
2003)17
Uncertain Uncertain Low risk Low risk Low risk Uncertain 4
GUEPARD 
(Soubrier et al., 
2009)19
Uncertain Uncertain High risk High risk Low risk Low risk 3
interval (RR = 0.86, 95% CI: 0.74; 0.99). ACR50 and ACR70 re-
sponses at 52 weeks, and ACR20, ACR50 and ACR70 responses 
at 104 weeks were not statistically signifi cant. This was also 
the only study that compared the combination ADA + MTX 
with ADA as monotherapy and the fi rst group showed better 
ACR20, ACR50 and ACR70 responses at 52 and 104 weeks.18
Patients undergoing combination therapy (ADA+ 
DMARDs) showed greater reduction in HAQ scale. The differ-
ence in means between groups at 24 weeks was -0.32 (-0.40; 
-0.24) and at 52 weeks of -0.32 (-0.39; -0.24).18,19,21,26,27 There 
was no signifi cant heterogeneity (I2 = 0% P = 0.99 and 0.60 for 
24 and 52 weeks, respectively) (Table 3). Only the PREMIER 
study reported HAQ outcome at 104 weeks and the differ-
ence in means (95% CI) was -0.10 with non-signifi cant 95% 
CI (-0.21; 0.01).18  
The comparison of ADA vs. MTX was performed only by 
PREMIER study, which showed a difference in HAQ scale of 
zero between the groups at 52 and 104 weeks. This was also 
the only study that compared the combination with ADA + 
MTX with ADA as monotherapy. At 52 weeks, the fi rst group 
showed greater reduction in HAQ scale (difference in means 
of -0.30, 95% CI: -0.41; -0.19); however, this result was not 
maintained at 104 weeks (difference in means of -0.10, 95% 
CI: -0.22; 0.02).18
Jamal et al. showed that the difference between ADA + 
MTX and placebo + MTX in relation to HAQ scale was higher 
in patients with up to three years of disease, when com-
pared to patients with established RA, albeit not signifi cant 
(P >  0.05).22
Kimel et al. used data from the PREMIER study and report-
ed that patients with RA treated with ADA + MTX and MTX 
monotherapy had lower scores on the physical component 
summary of the SF-36 when compared with the reference 
population of the United States at 12 weeks. At 104 weeks of 
treatment, there was a difference only for the MTX group.20 
It was not possible to perform a meta-analysis for ra-
diological outcomes, as the articles did not indicate stan-
dard deviation or other measure of variability that would 
allow combination of data. Keystone et al. showed that at 
52 weeks, the patients who received ADA + MTX showed 
better radiographic progression measured by the modifi ed 
Sharp score, when compared with the placebo + MTX group 
(increase of 0.8 vs. 2.7, P ≤ 0.001). Improvements were also 
found in the scores for erosion (increase of 0.4 versus 1.6, p 
≤ 0.001) and joint space narrowing (increase of 0.1 vs. 1.0, P 
≤ 0.01).21 
In the PREMIER study, at 26 weeks, the increase in the 
modifi ed Sharp index was 0.8, 2.1 and 3.5 for patients on 
the combination therapy, MTX and ADA, respectively (P < 
0.05 for all comparisons). At 52 and 104 weeks of treatment, 
these values  were 1.3 and 1.9 (ADA + MTX), 3.0 and 5.5 (ADA) 
and 5.7 to 10.4 (MTX, with P < 0.05 for all comparisons).18 
The meta-analysis showed a greater risk of loss to fol-
low-up for lack of effi cacy for placebo + DMARDs group in up 
to 104 weeks (RR 0.31 95% CI: 0.21; 0.45) with no statistical 
heterogeneity, I2 = 0% and P = 0,80.17,18,21,27 Loss to follow-up 
due to adverse reactions showed RR of 1.55 (95% CI: 1.08; 
2.21) in up to 104 weeks, favoring the placebo + DMARDs 
group, with no statistical heterogeneity, I2 = 0%, P = 0.61 (Ta-
ble 3).17,18,21,23,26,27 
The PREMIER study showed no difference in the risk of 
loss to follow-up due to lack of effi cacy and adverse reac-
tions between groups ADA and MTX. On the other hand, 
when comparing the group ADA + MTX with ADA monother-
apy, RR (95% CI) of 3.91 (2.18; 7.02) was observed for loss to 
follow-up due to lack of effi cacy, favoring the combination.18 
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Adalimumab 40 mg versus placebo
The results of this comparison are shown for the period of 24/26 
weeks. The combination of these studies resulted in RR (95% CI) 
of 2.67 (1.89; 3.77), 3.19 (1.81; 5.62) and 7.90 (2.42; 25.80) for ACR20, 
ACR50 and ACR70, respectively, favoring the ADA group. There 
was no statistical heterogeneity (I2 = 0%, P = 0.45, 0.46 and 0.73 
for ACR20, ACR50 and ACR70, respectively) (Table 3).24,28 
The difference in means (95% CI) in HAQ scale between 
the ADA and placebo groups was -0.31 (-0.42; -0.19), I2 = 0%, 
P = 0.93, favoring the ADA group. The RR (95% CI) for loss to 
follow-up due to adverse events was 3.34 (1.27; 8.80), favoring 
the placebo group and with no signifi cant heterogeneity (I2 = 
0%, P = 0.55, Table 3).24,28 
Safety
Adalimumab 40 mg + DMARDs vs. placebo + DMARDs
The results of meta-analyses of adverse events showed no 
statistical signifi cance, except for the reaction at the injection 
site at up to 52 weeks, which favored the placebo + DMARDs 
group, but with borderline confi dence interval (RR: 1.32; 95% 
CI: 1.02; 1.71).17,21,23,26 All meta-analyses showed low statistical 
heterogeneity (Table 3).
Adalimumab 40 mg vs. placebo
Only reaction at the injection site showed a statistically signifi -
cant result with RR (95% CI) of 12.45 (3.92; 39.52) at 24/26 weeks, 
with no statistical heterogeneity (I2 = 0%, P = 0.86). The RR (95% 
CI) for serious adverse reactions was 1.24 (0.49; 3.13), with sub-
stantial heterogeneity (I2 = 68% and P = 0.08, Table 3).24,28
The study by van de Putte et al. at 26 weeks, reported that 
more patients that used ADA, when compared to the placebo 
group, reported headache (18.6% vs. 10.9%), skin rash (20.4% 
vs. 5.5%) and pruritus (11.5% vs. 0.9%, P < 0.05 for all com-
parisons). Severe infections occurred at similar frequencies in 
both groups (2.3% ADA vs. 0.0% placebo).24
In the CHANGE study, at 24 weeks, the frequency of infec-
tions (45.1% vs. 36.8%) and severe infections (6.6% vs. 1.1%) 
Fig. 2 – Meta-analysis of ACR20, ACR50 and ACR70 responses in up to 24 weeks. Adalimumab 40 mg every two weeks + 
DMARDs vs. placebo + DMARDs. 
DMARDs,  disease-modifying antirheumatic drugs; MTX, methotrexate. ADA, adalimumab.
Statistics I2 >40% indicates statistical heterogeneity between the studies. A P value < 0.10 in the Chi-square test indicates 
heterogeneity.
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showed no statistically signifi cant differences between the 
ADA and placebo groups.28 
Discussion
The results of the systematic review and meta-analysis 
showed that patients who were treated with ADA 40 mg ev-
ery two weeks associated with MTX showed better effi cacy 
results and lower radiographic progression when compared 
to patients receiving placebo + MTX. The risk of occurrence 
of loss to follow-up due to lack of effi cacy was higher in the 
placebo + MTX group, while the loss due to adverse reactions 
was higher in the ADA + MTX group. However, these results 
are more robust for a follow-up of 24 weeks, as only two stud-
ies evaluated the patients for 52 and only one for 104 weeks.
There was no statistically signifi cant difference regard-
ing the effi cacy and loss to follow-up due to lack of effi cacy 
between the ADA monotherapy group with ADA 40 mg every 
two weeks and MTX monotherapy, whereas radiographic pro-
gression for the group that used ADA showed better results. 
The combination of ADA 40 mg every other week + MTX when 
compared to ADA 40 mg every two weeks as monotherapy 
showed better outcomes in ACR response and radiographic 
progression, whereas in the HAQ scale the result was statisti-
cally signifi cant only at 52 weeks and also favorable to the 
combination. The risk of loss to follow-up due to lack of ef-
fi cacy was higher for the monotherapy. These comparisons 
were evaluated by only one trial.18 
Patients that received ADA 40 mg every two weeks as 
monotherapy showed better effi cacy outcomes when com-
pared to placebo at 24/26 weeks, and loss due to adverse reac-
tions favored the placebo group.
Meta-analyses of adverse events were not statistically sig-
nifi cant when comparing “ADA 40 mg every two weeks + MTX 
versus placebo + MTX” and “ADA 40 mg every two weeks vs. 
placebo,” with the exception of reactions at the injection site, 
which is expected to be higher in the group that used the anti-
TNF agent. It is noteworthy that the RR in the comparison of 
“ADA 40 mg every two weeks + MTX versus placebo + MTX” 
showed borderline confi dence interval for this event.
An inherent characteristic of clinical trials is that they 
are carried out in a carefully selected population and, there-
fore, do not represent the actual population. Furthermore, 
most of the studies included were performed for a short 
period of time (one study lasted two years). Thus, the re-
sults of clinical trials have low external validity and should 
be extrapolated to clinical practice with caution, especially 
Table 3 – Results of the meta-analyses for HAQ, adverse events and loss to follow-up for comparisons ADA 40 mg every 
two weeks+ DMARDs vs. placebo + DMARDs and ADA 40 mg every two weeks vs. placebo.
Outcome Period (weeks) Studies Participants Measure of effect 
(95%CI) *
I2 (%)a P valueb
ADA 40 mg + MMCD vs. placebo + MMCD
HAQ Up to 24 419,21,26,27 729 -0.32 (-0.40; -0.24) 0 0.99
HAQ 52 218,21 932 -0.32 (-0.39; -0.24) 0 0.60
Loss due to lack 
of effi cacy
Up to 104 417,18,21,27 1696 0.31 (0.21; 0.45) 0 0.80
Loss due to 
adverse 
reaction 
Up to 104 617,18,21,23,26,27 1872 1.55 (1.08; 2.21) 0 0.61
Adverse reactions Up to 104 517,18,21,23,27 1955 1.03 (1.00; 1.05) 0 0.67
Severe adverse 
reactions 
Up to  24 317,23,27 811 0.84 (0.58; 1.20) 0 0.54
Infections Up to 24 317,23,27 1171 1.07 (0.93; 1.24) 0 0.59
Severe infections Up to 104 617,18,21,23,26,27 2014 1.73 (0.72; 4.14) 27 0.23
Reaction at the 
injection site
Up to 52 417,21,23,26 1219 1.32 (1.02; 1.71) 2 0.38
Tuberculosis Up to 104 517,18,21,23,27 1743 2.25 (0.46; 11.02) 0 0.96
Cancer Up to 104 617,18,21,23,26,27 2226 1.02 (0.30; 3.47) 0 0.53
Death Up to  104 517,18,21,23,27 1743 2.38 (0.52; 10.84) 0 0.88
ADA 40 mg vs. placebo
ACR20 24/26 224,28 401 2.67 (1.89; 3.77) 0 0.45
HAQ 24/26 224,28 401 -0.31 (-0.42; -0.19) 0 0.93
Loss due to 
adverse 
reaction
24/26 224,28 401 3.34 (1.27; 8.80) 0 0.55
Severe adverse 
reactions
24/26 224,28 401 1.24 (0.49; 3.13) 68 0.08
Reaction at the 
injection site
24/26 224,28 401 12.45 (3.92; 39.52) 0 0.68
ACR, American College of Rheumatology; ADA, adalimumab; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment 
Questionnaire.
* Data on relative risk for dichotomous outcomes and difference of means for continuous outcomes with a confi dence interval of 95%. 
  Statistics I2 > 40% indicates statistical heterogeneity between studies. 
bP-value < 0.10 at the chi-square test indicates statistical heterogeneity between studies. Superscript numbers indicate the studies used in the 
meta-analyses.
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safety outcomes, as rare adverse events are often reported 
in post-marketing studies. 
Therefore, it is important to consider the results of adverse 
events from studies with longer time of follow-up. An open 
label extension of fi ve years of the PREMIER study showed 
that the rate of severe infections was 3.3 events per 100 pa-
tient-years, and that there were two cases of tuberculosis (0.1 
/ 100 patient-years), a case of lymphoma (< 0.1/100 patient-
years) and one non-melanoma skin cancer (< 0.1/100 patient-
years), in addition to 11 other reports of malignant tumors.29 
The open label phase of the DE019 study, which also lasted 
fi ve years, reported a rate of severe infections of 4.4 per 100 
patient-years and two cases of tuberculosis. The rate of non-
melanoma skin cancer was 1.1/100 patient-years and other 
types of cancer, 1.5/100 patient-years.30 In the early open-label 
stage of the two studies, all patients started using ADA 40 mg 
once every 15 days. 
A meta-analysis of cohort studies indicated that patients 
with RA that used TNF antagonists showed a 40% increase in 
the risk of severe infections when compared with patients 
who used DMARDs (RR: 1.37, 95% CI: 1.18; 1.60).31 
In clinical trials with TNF blockers, it is common to perform 
screening for latent TB infection and prophylactic treatment 
in positive cases. This is also recommended by the treatment 
guidelines and occurs in clinical practice.11 Nevertheless, 
there have been cases of tuberculosis related to the use of 
these drugs. The Spanish registry of adverse events of biologi-
cal therapy in rheumatic diseases reported that the incidence 
of tuberculosis before 2002 was 472 per 100,000 patient-years 
and, from 2002 to January 2006, when recommendations for 
screening and prophylactic treatment of patients with latent 
tuberculosis began to be disclosed, the incidence decreased to 
172 cases per 100,000 patient-years.32
The British Society for Rheumatology reported in 2008 that 
the risk of tuberculosis in patients treated with adalimumab 
was 217/100.000 person-years, while the mean annual inci-
dence of the UK population was 13.2 events/ 100.000 person-
years. Almost half of the cases were diagnosed after the end 
of treatment, indicating that the surveillance for tuberculosis 
should continue even after therapy cessation.33
A systematic review of clinical trials and cohorts shows 
that the combination of adalimumab (or other biological 
agent, such as etanercept, infl iximab, or rituximab) with MTX 
achieves better clinical responses than monotherapy with the 
biological agent alone.34 Clinical trials that have shown the 
benefi t of ADA monotherapy compared the biological agent 
with placebo and in the PREMIER study, in general, there was 
no difference between the ADA and MTX groups.18,24,28
The GUEPARD study showed that, although the ADA + MTX 
combination provides faster responses, it does not offer the 
best results of effi cacy and radiological indices after one year, 
when compared with patients who started treatment with 
MTX as monotherapy, which would not justify initiating treat-
ment of RA with the biological agent.19
Comparisons with other systematic reviews 
Other systematic reviews corroborate the results shown here, 
demonstrating greater effi cacy of ADA compared to control 
in the short and long term. However, caution is needed when 
interpreting long-term results, as studies lasting more than 
52 weeks are scarce and the meta-analyses usually show high 
heterogeneity.4,35-37
Wiens et al. showed that the result of the meta-analysis 
for ACR responses at 52 weeks is statistically signifi cant and 
favorable to the group using ADA, which differs from the re-
sults found in this review.38 This difference regarding the di-
rection of results may be related to the method used by the 
authors, using both arms with ADA of the DE019 study, count-
ing the results of placebo group twice, in addition to com-
bining groups with different doses of ADA, which may have 
skewed the results.21
Jamal et al. showed that there is no difference in ACR re-
sponse when comparing patients with early and established 
disease.22 On the other hand, systematic reviews of TNF block-
ers have found that the ACR response was better in patients 
with more than two years of disease and better results were 
seen in patients with previous MTX use.33,37
Limitations
The publication bias is a concern in any systematic review. It 
is possible that studies suggesting benefi ts of the intervention 
of interest are published, while those of which results point 
in another direction remain unpublished. In this situation, a 
systematic review of published studies can identify a spuri-
ous benefi t of an important effect or fail to indicate important 
adverse events.39 
Overall, the evidence can be considered strong, as the stud-
ies included in this review had good methodological quality 
and low risk of bias, except for the GUEPARD study, of which 
design was not double-blind.19 It was observed that the results 
remain similar after the exclusion of this study.
Implications for research and clinical practice 
No studies were found comparing Adalimumab with other 
biological agents, demonstrating a lack of knowledge in this 
area, as it would be important for clinical practice to know 
the comparative effi cacy and safety profi les between biologi-
cal agents, considering that in relation to placebo and MTX, 
they are already well established. 
This study showed that Adalimumab at a dose of 40 mg 
every two weeks is effective in the treatment of RA and well 
tolerated in the short term. The effi cacy of Adalimumab was 
demonstrated in monotherapy and associated to DMARDs, 
particularly MTX, although the evidence for combined use is 
more robust. The available scientifi c evidence corroborates the 
recommendations of the Brazilian Society of Rheumatology for 
RA treatment: the use of biological agents is indicated for pa-
tients who persist with disease activity despite treatment in-
cluding at least two regimens with DMARDs, of which at least 
one is a combination of DMARDs. The use of biological agents 
must be performed associated to a DMARD, preferably MTX.3 
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